Novo Nordisk’s CagriSema shows 15.7% weight loss in second pivotal trial

Novo Nordisk’s CagriSema demonstrated weight loss of 15.7% in patients with both obesity and type 2 diabetes who took the drug for more than a year, the company said Monday. ...